Video
Dr. Tagawa on next steps with PSMA-targeted therapies in prostate cancer
Author(s):
Video Player is loading.
Scott T. Tagawa, MD, MS, FACP, discusses the next research steps with PSMA-targeted therapies in prostate cancer, including combining radionuclides with other agents and exploring novel approaches to targeting PSMA, such as antibodies. Tagawa is a professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Related Content
